Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Proteinuria is not only a marker of chronic kidney disease (CKD) progression, but also a
marker of cardiovascular disease and death. In previous studies, active vitamin D deficiency
is associated with cardiovascular risk factors such as albuminuria, diabetes mellitus, and
lower glomerular filtration rate (GFR). And calcitriol was shown to have a preventive effect
in progressive glomerular damage in a renal ablation model. Calcitriol, an active form of
vitamin D (1,25-dihydroxyvitamin-D3), is commonly used for the treatment of secondary
hyperparathyroidism in patients with advanced chronic kidney diseases.
Therefore, the objective of this study is to evaluate the anti-proteinuric effect of
calcitriol in non-diabetic kidney disease patients. They will be treated with calcitriol and
placebo for 24 weeks and observed for 24 weeks after treatment. Proteinuria, renal function,
serum and urinary inflammatory markers, and adverse event will be monitored.